Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

2/27/24 8:11:41 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ENSC alert in real time by email

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).

Get the next $ENSC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENSC

Date	Price Target	Rating	Analyst
11/30/2021	$4.00	Buy	Lake Street

More analyst ratings

$ENSC
Financials

Live finance-specific insights

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are proud of the significant progress Ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, PF614, and our overdose protection product, PF614-MPAR.
3/15/24 8:00:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.Corporate Update Conference CallDate: Tuesday, April 11, 2023Time: 11:00am ETU.S. Dial-in: 1-877-407-0792International Dial-in: 1-201-689-8263Webcast: ENSC Corporate Upd
4/11/23 8:10:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, excl
2/1/23 8:05:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care

$ENSC
Press Releases

Fastest customizable press release news feed in the world

Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPARSubmitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the third quarter ended September 30, 2024.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team has made significant progress in the third quarter, and we have line of sigh
11/12/24 4:15:00 PM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to November 14, 2024, to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1) as of September 30, 2024, with filing of its Form 10-Q. Additionally, the Company received an exten
11/7/24 8:00:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit
~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA.Dr. Kirkpatrick's presentation "When All You Have is a Hammer ... A New Approach to Soften the
10/8/24 8:00:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care

$ENSC
Leadership Updates

Live Leadership Updates

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and
4/18/22 4:05:00 PM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took
2/8/22 4:01:00 PM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston. Her early research was vi
10/26/21 8:00:00 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care

$ENSC
Market Insights

Live Market Insights

Ensysce Biosciences To Host Symposium On Safer Analgesics At IASP 2024 World Congress; CEO Dr. Lynn Kirkpatrick To Introduce Event Featuring Pain Experts Dr. Lars Arendt-Nielsen And Dr. William Schmidt
7/23/24 8:10:39 AM ET
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
6/21/24 8:22:44 AM ET
$BRNS
$CLOV
$DMTK
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Computer Software: Programming Data Processing
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
6/20/24 4:31:11 PM ET
$ALZN
$CLNN
$CLOV
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Chat with this insight

Recent Analyst Ratings for
$ENSC

$ENSC
Financials

Live finance-specific insights

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

$ENSC
Press Releases

Fastest customizable press release news feed in the world

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

$ENSC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Ensysce Biosciences with a new price target

$ENSC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

$ENSC
Leadership Updates

Live Leadership Updates

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

$ENSC
Market Insights

Live Market Insights

Ensysce Biosciences To Host Symposium On Safer Analgesics At IASP 2024 World Congress; CEO Dr. Lynn Kirkpatrick To Introduce Event Featuring Pain Experts Dr. Lars Arendt-Nielsen And Dr. William Schmidt

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's After-Market Session

$ENSC
SEC Filings

Ensysce Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Ensysce Biosciences Inc.

SEC Form 10-Q filed by Ensysce Biosciences Inc.

$ENSC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Gower Bob G bought $182,350 worth of shares (379,300 units at $0.48), increasing direct ownership by 50% to 1,132,395 units

SEC Form 4: Gower Bob G bought $500,000 worth of shares (357,143 units at $1.40), increasing direct ownership by 90% to 753,095 units

SEC Form 4 filed by Chang William H

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Chat with this insight

Recent Analyst Ratings for $ENSC

$ENSC Financials

Live finance-specific insights

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

$ENSC Press Releases

Fastest customizable press release news feed in the world

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

$ENSC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Ensysce Biosciences with a new price target

$ENSC Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

SEC Form SC 13G filed by Ensysce Biosciences Inc.

$ENSC Leadership Updates

Live Leadership Updates

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

$ENSC Market Insights

Live Market Insights

Ensysce Biosciences To Host Symposium On Safer Analgesics At IASP 2024 World Congress; CEO Dr. Lynn Kirkpatrick To Introduce Event Featuring Pain Experts Dr. Lars Arendt-Nielsen And Dr. William Schmidt

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's After-Market Session

$ENSC SEC Filings

Ensysce Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Ensysce Biosciences Inc.

SEC Form 10-Q filed by Ensysce Biosciences Inc.

$ENSC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Gower Bob G bought $182,350 worth of shares (379,300 units at $0.48), increasing direct ownership by 50% to 1,132,395 units

SEC Form 4: Gower Bob G bought $500,000 worth of shares (357,143 units at $1.40), increasing direct ownership by 90% to 753,095 units

SEC Form 4 filed by Chang William H

Recent Analyst Ratings for
$ENSC

$ENSC
Financials

$ENSC
Press Releases

$ENSC
Analyst Ratings

$ENSC
Large Ownership Changes

$ENSC
Leadership Updates

$ENSC
Market Insights

$ENSC
SEC Filings

$ENSC
Insider Trading